Starší publikace (2012 - 2013)

Publikace 2013

MM a MGUS

  1. Avet-Loiseau H, Durie BG, Cavo M, Attal M, Gutierrez N, Haessler J, Goldschmidt H, Hajek R, Lee JH, Sezer O, Barlogie B, Crowley J, Fonseca R, Testoni N, Ross F, Rajkumar SV, Sonneveld P, Lahuerta J, Moreau P, Morgan G; International Myeloma Working Group. Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project. Leukemia. 2013 Mar;27(3):711-7. doi: 10.1038/leu.2012.282. IF 10,164
  2. Čermáková Z, Gottwaldová J, Dastych M, Adam Z, Zahradová L. Efficient use of basic biochemical methods to prove the presence of monoclonal protein in the clinical diagnosis of malignant monoclonal gammopathy. Clin Chem Lab Med. 2013 Oct 1;51(10):e243-5. doi: 10.1515/cclm-2013-0090. IF 3,009
  3. Dementyeva E, Kryukov F, Kubiczkova L, Nemec P, Sevcikova S, Ihnatova I, Jarkovsky J, Minarik J, Stefanikova Z, Kuglik P, Hajek R. Clinical implication of centrosome amplification and expression of centrosomal functional genes in multiple myeloma. J Transl Med. 2013 Mar 23;11:77. doi: 10.1186/1479-5876-11-77. IF 3,459
  4. Dimopoulos M, Siegel DS, Lonial S, Qi J, Hajek R, Facon T, Rosinol L, Williams C, Blacklock H, Goldschmidt H, Hungria V, Spencer A, Palumbo A, Graef T, Eid JE, Houp J, Sun L, Vuocolo S, Anderson KC. Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study. Lancet Oncol. 2013 Oct;14(11):1129-40. doi: 10.1016/S1470-2045(13)70398-X. IF 25,117
  5. Dimopoulos MA, Delforge M, Hájek R, Kropff M, Petrucci MT, Lewis P, Nixon A, Zhang J, Mei J, Palumbo A. Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial. Haematologica. 2013 May;98(5):784-8. doi: 10.3324/haematol.2012.074534. IF 5,935
  6. Fernández de Larrea C, Kyle RA, Durie BG, Ludwig H, Usmani S, Vesole DH, Hajek R, San Miguel JF, Sezer O, Sonneveld P, Kumar SK, Mahindra A, Comenzo R, Palumbo A, Mazumber A, Anderson KC, Richardson PG, Badros AZ, Caers J, Cavo M, LeLeu X, Dimopoulos MA, Chim CS, Schots R, Noeul A, Fantl D, Mellqvist UH, Landgren O, Chanan-Khan A, Moreau P, Fonseca R, Merlini G, Lahuerta JJ, Bladé J, Orlowski RZ, Shah JJ; International Myeloma Working Group. Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia. 2013 Apr;27(4):780-91. doi: 10.1038/leu.2012.336. IF 10,164
  7. Grzasko N, Hus M, Pluta A, Jurczyszyn A, Walter-Croneck A, Morawska M, Chocholska S, Hajek R, Dmoszynska A. Additional genetic abnormalities significantly worsen poor prognosis associated with 1q21 amplification in multiple myeloma patients. Hematol Oncol. 2013 Mar;31(1):41-8. doi: 10.1002/hon.2018. IF 2,036
  8. Hájek R, Plonková H, Gumulec J. Thalidomide in the treatment of multiple myeloma: focus on combination with bortezomib. Klin Onkol. 2013;26(3):163-9.
  9. Hajek R, Okubote SA, Svachova H. Myeloma stem cell concepts, heterogeneity and plasticity of multiple myeloma. Br J Haematol. 2013 Dec;163(5):551-64. doi: 10.1111/bjh.12563. IF 4,942
  10. Kryukov F, Dementyeva E, Kubiczkova L, Jarkovsky J, Brozova L, Petrik J, Nemec P, Sevcikova S, Minarik J, Stefanikova Z, Kuglik P, Hajek R. Cell cycle genes co-expression in multiple myeloma and plasma cell leukemia. Genomics. 2013 Oct;102(4):243-9. doi: 10.1016/j.ygeno.2013.06.007. IF 3,010
  11. Kryukov F, Nemec P, Dementyeva E, Kubiczkova L, Ihnatova I, Budinska E, Jarkovsky J, Sevcikova S, Kuglik P, Hajek R. Molecular heterogeneity and centrosome-associated genes in multiple myeloma. Leuk Lymphoma. 2013 Sep;54(9):1982-8. doi: 10.3109/10428194.2013.764416. IF 2,301
  12. Kubiczková L, Dúcka M, Sedlaříková L, Kryukov F, Hájek R, Sevčíková S. Cyclins d in regulation and dysregulation of the cell cycle in multiple myeloma. Klin Onkol. 2013;26(5):313-8.
  13. Kubiczková L, Matějíková J, Sedlaříková L, Kryukov F, Hájek R, Sevčíková S. Proteasome inhibitors in treatment of multiple myeloma. Klin Onkol. 2013;26(1):11-8. Review.
  14. Ludwig H, Viterbo L, Greil R, Masszi T, Spicka I, Shpilberg O, Hajek R, Dmoszynska A, Paiva B, Vidriales MB, Esteves G, Stoppa AM, Robinson D Jr, Ricci D, Cakana A, Enny C, Feng H, van de Velde H, Harousseau JL. Randomized phase II study of bortezomib, thalidomide, and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myeloma. J Clin Oncol. 2013 Jan 10;31(2):247-55. doi: 10.1200/JCO.2011.39.5137. IF 18,038
  15. Mathu Raja KR, Hajek R. Contribution of regulatory T cells to immunosuppression and disease progression in multiple myeloma patients. Oncoimmunology. 2013 Sep 1;2(9):e25619.
  16. Matějíková J, Kubiczková L, Sedlaříková L, Potáčová A, Hájek R, Sevčíková S. Degradation of proteins by ubiquitin proteasome pathway. Klin Onkol. 2013;26(4):251-6.
  17. Minarik J, Sandecka V, Maisnar V, Gregora E, Spicka I, Starostka D, Plonkova H, Jarkovsky J, Walterova L, Wrobel M, Adamova D, Pika T, Melicharova H, Pour L, Radocha J, Pavlicek P, Straub J, Gumulec J, Bacovsky J, Adam Z, Scudla V, Hajek R. 10 years of experience with thalidomide in multiple myeloma patients: report of the Czech Myeloma Group. Leuk Res. 2013 Sep;37(9):1063-9. doi: 10.1016/j.leukres.2013.06.019. IF 2,764
  18. Orság J, Pika T, Kosatíková Z, Lochman P, Žamboch K, Minařík J, Hrubý M, Ščudla V, Zadražil J. Hemodialýza s použitím „high cut-off“ membrán při selhání ledvin u mnohočetného myelomu – první zkušenosti. Klin. Biochem. Metab., 21 (42), 2013, No. 2, p. 88–92.
  19. Pika T, Lochman P, Maisnar V, Tichý M, Minařík J, Hájek R, Ščudla V. Klinicko-laboratorní aspekty biklonální gamapatie nejistého významu – BGUS. Klin. Biochem. Metab., 21 (42), 2013, No. 2, p. 83–87
  20. Pika T, Lochman P, Flodr P, Mičková P, Novák M, Jehlíková Z, Hamplová A, Minařík J, Bačovský J, Kučerová L, Jarošová M, Ščudla V. Klinické aspekty „pravé“ nesekretorické formy mnohočetného myelomu. Transfuze Hematol. dnes, 19, 2013, No. 1, p. 27-32.
  21. Radocha J, Maisnar V, Zavrelová A, Cermanová M, Lánská M, Kmonícek M, Jebavý L, Bláha M, Malý J, Zák P. Fifteen years of single center experience with stem cell transplantation for multiple myeloma: a retrospective analysis. Acta Medica (Hradec Kralove). 2013;56(1):9-13.
  22. Richardson PG, Mitsiades CS, Laubach JP, Hajek R, Spicka I, Dimopoulos MA, Moreau P, Siegel DS, Jagannath S, Anderson KC. Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma. Leuk Res. 2013 Jul;37(7):829-37. doi: 10.1016/j.leukres.2013.03.006. IF 2,764
  23. San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, Delforge M, Jiang B, Mateos MV, Anderson KC, Esseltine DL, Liu K, Deraedt W, Cakana A, van de Velde H, Richardson PG. Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma. J Clin Oncol. 2013 Feb 1;31(4):448-55. doi: 10.1200/JCO.2012.41.6180. IF 18,038
  24. Sevcikova S, Kubiczkova L, Sedlarikova L, Slaby O, Hajek R. Serum miR-29a as a marker of multiple myeloma. Leuk Lymphoma. 2013;54(1):189-91. IF 2,301
  25. Smetana J, Berankova K, Zaoralova R, Nemec P, Greslikova H, Kupska R, Mikulasova A, Frohlich J, Sevcikova S, Zahradova L, Krejci M, Sandecka V, Almasi M, Kaisarova P, Melicharova H, Adam Z, Penka M, Jarkovsky J, Jurczyszyn A, Hajek R, Kuglik P. Gain(1)(q21) is an unfavorable genetic prognostic factor for patients with relapsed multiple myeloma treated with thalidomide but not for those treated with bortezomib. Clin Lymphoma Myeloma Leuk. 2013 Apr;13(2):123-30. doi: 10.1016/j.clml.2012.11.012. IF 1,667
  26. Špička I, Klánová M. Multiple myeloma. Vnitr Lek. 2013 Jul;59(7):627-30.
  27. Szturz P, Adam Z, Vašků V, Feit J, Krejčí M, Pour L, Hájek R, Mayer J. Complete remission of multiple myeloma associated scleredema after bortezomib-based treatment. Leuk Lymphoma. 2013 Jun;54(6):1324-6. doi: 10.3109/10428194.2012.738816. IF 2,301
  28. Uherková L, Vančurová I, Vyhlídalová I, Pleschnerová M, Spička I, Mihalová R, Březinová J, Hodný Z, Cermáková K, Polanská V, Marinov I, Jedelský PL, Kuželová K, Stöckbauer P. Novel human multiple myeloma cell line UHKT-893. Leuk Res. 2013 Mar;37(3):320-6. doi: 10.1016/j.leukres.2012.12.004. IF 2,764

Amyloidóza

  1. Adam Z, Krejčí J, Krejčí M, Němec P, Spinarová L, Zampachová V, Cermáková Z, Pika T, Pour L, Kořístek Z, Tomíška M, Szturz P, Král Z, Mayer J. Heart transplantation and the subsequent treatment of AL amyloidosis. Vnitr Lek. 2013 Feb;59(2):136-47.
  2. Adam Z, Sčudla V, Krejčí M, Cermáková Z, Pour L, Král Z. Treatment of AL amyloidosis in 2012; the benefit of new drugs (bortezomib, thalidomide, and lenalidomide). Summary of published clinical trials. Vnitr Lek. 2013 Jan;59(1):37-58. Review.
  3. Fikrle, M., Paleček, T., Kuchynka, P., Němeček, E., Bauerová, L., Straub, J., Ryšavá, R. Cardiac amyloidosis: A comprehensive review. Cor et Vasa. 2013, 55(1), e60-e75. ISSN 0010-8650.
  4. Pika T, Lochman P, Vymětal J, Metelka R, Minařík J, Látalová P, Zapletalová J, Bačovský J, Sčudla V. Attainment of Complete Hematological Remission is Crucial for Extended Survival of AL Amyloidosis Patients with Cardiac Involvement. Klin Onkol. 2013;26(5):343-7.
  5. Pika T, Lochman P, Vymětal J, Metelka R, Flodr P, Minařík J, Látalová P, Zapletalová J, Bačovský J, Sčudla V. The importance of cardiac bio-marker assay for the stratification and monitoring of AL amyloidosis patients - single center experience. Vnitr Lek. 2013 Fall;59(9):776-81.
  6. Pika T, Lochman P, Flodr P, Minařík J, Látalová P, Bačovský J, Ščudla V. Význam stanovení vybraných laboratorních parametrů v diagnostice, stratifikaci a sledování nemocných s AL amyloidózou. Klin. Biochem. Metab., 21 (42), 2013, No. 2, p. 79–82.
  7. Szturz P, Kyclová J, Moulis M, Navrátil M, Adam Z, Vaníček J, Mayer J. Extensive Al amyloidosis presenting with recurrent liver hemorrhage and hemoperitoneum: case report and literature review. Klin Onkol. 2013;26(1):49-52. Review.

 

2012

  1. Adam Z, Elleder M, Moulis M, Tichý M, Cervinková I, Rehák Z, Koukalová R, Fojtík Z, Hanke I, Pour L, Krejčí M, Zahradová L, Szturz P, Hájek R, Král Z, Mayer J. The role of PET-CT in decision making on the treatment of localized nodular form of pulmonary AL-amyloidosis. Vnitr Lek. 2012 Mar;58(3):241-52.
  2. Al-Sahmani M, Trnavská I, Antošová M, Antošová L, Kissová J, Kaisarová B, Adam Z, Buliková A, Penka M, Hájek R. Prognostic significance of morphology in multiple myeloma. Klin Onkol. 2012;25(2):103-9.
  3. Buresova I, Cumova J, Kovarova L, Stossova J, Dementyeva E, Kryukov F, Sevcikova S, Svachova H, Hajek R. Bone marrow plasma cell separation - validation of separation algorithm. Clin Chem Lab Med. 2012;50(6):1139-40. IF 2,150
  4. Cumová J, Jedličková L, Potěšil D, Sedo O, Stejskal K, Potáčová A, Zdráhal Z, Hájek R. Comparative plasma proteomic analysis of patients with multiple myeloma treated with bortezomib-based regimens. Klin Onkol. 2012;25(1):17-25.
  5. Fišerová B, Kubiczková L, Sevčíková S, Hájek R. [Implication of bone marrow microenvironment in pathogenesis of multiple myeloma]. Klin Onkol. 2012;25(4):234-40. Review.
  6. Garderet L, Iacobelli S, Moreau P, Dib M, Lafon I, Niederwieser D, Masszi T, Fontan J, Michallet M, Gratwohl A, Milone G, Doyen C, Pegourie B, Hajek R, Casassus P, Kolb B, Chaleteix C, Hertenstein B, Onida F, Ludwig H, Ketterer N, Koenecke C, van Os M, Mohty M, Cakana A, Gorin NC, de Witte T, Harousseau JL, Morris C, Gahrton G. Superiority of the Triple Combination of Bortezomib-Thalidomide-Dexamethasone Over the Dual Combination of Thalidomide-Dexamethasone in Patients With Multiple Myeloma Progressing or Relapsing After Autologous Transplantation: The MMVAR/IFM 2005-04 Randomized Phase III Trial From the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2012;30(20):2475-82. IF 18,372
  7. Grzasko N, Hus M, Chocholska S, Pluta A, Hajek R, Dmoszynska A. 1q21 amplification with additional genetic abnormalities but not isolated 1q21 gain is a negative prognostic factor in newly diagnosed patients with multiple myeloma treated with thalidomide-based regimens. Leuk Lymphoma. 2012;53(12):2500-3. PubMed PMID: 22497640. IF 2,580
  8. Hájek R, Bryce R, Ro S, Klencke B, Ludwig H. Design and rationale of FOCUS (PX-171-011): A randomized, open-label, phase 3 study of carfilzomib versus best supportive care regimen in patients with relapsed and refractory multiple myeloma (R/R MM). BMC Cancer. 2012;12:415. doi: 10.1186/1471-2407-12-415. IF 3,011
  9. Ross F, Avet-Loiseau H, Ameye G, Gutierrez NC, Liebisch P, O' Connor S, Dalva K, Fabris S, Testi AM, Jarosova M, Collin A, Kerndrup G, Kuglik P, Ladon D, Bernasconi P, Maes B, Zemanova Z, Michalova K, Michaux L, Neben K, Hermansen NE, Rack K, Rocci A, Protheroe R, Chiecchio L, Poirel HA, Sonneveld P, Nyegaard M, Johnsen HE. Report from the european myeloma network on interphase FISHin multiple myeloma and related disorders. Haematologica. 2012;97(8):1272-7 IF 6,424
  10. Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J, Haessler J, Feather J, Hoering A, Moreau P, Leleu X, Hulin C, Klein SK, Sonneveld P, Siegel D, Bladé J, Goldschmidt H, Jagannath S, Miguel JS, Orlowski R, Palumbo A, Sezer O, Rajkumar SV, Durie BG; on behalf of the International Myeloma Working Group; International Myeloma Working Group, Abildgaard N, Abonour R, Alexanian R, Alsina M, Anderson KC, Attal M, Avet-Loiseau H, Badros A, Baris D, Barlogie B, Bataille R, Beksaç M, Belch A, Ben-Yehuda D, Bensinger B, Leif Bergsagel P, Bird J, Bladé J, Boccadoro M, Cavo M, Chanan-Khan A, Ming Chen W, Child T, Chim J, Chng WJ, Comenzo R, Crowley J, Dalton W, Davies F, de Souza C, Delforge M, Dimopoulos M, Dispenzieri A, Drach J, Drake M, Durie BG, Einsele H, Facon T, Fantl D, Fermand JP, Fonseca R, Gahrton G, García-Sanz R, Gasparetto C, Gertz M, Gibson J, Giralt S, Goldschmidt H, Greipp P, Hajek R, Hardan I, Hari P, Harousseau JL, Hata H, Hattori Y, Heffner T, Ho J, Hungria V, Ida S, Jacobs P, Jagannath S, Johnsen H, Jian H, Joshua D, Jurczyszyn A, Kawano M, Kröger N, Kumar S, Kyle RA, Lacy M, Lahuerta JJ, Landgren O, Laubach J, Lee JH, Leleu X, Lentzsch S, Lokhorst H, Lonial S, Ludwig H, Maiolino A, Mateos M, Mehta J, Mellqvist UH, Merlini G, Mikhael J, Morales AR, Moreau P, Morgan G, Nari H, Munshi N, Niesvizky R, Nouel A, Novis Y, Orlowski R, Palumbo A, Pavlovsky S, Pilarski L, Powles R, Raje N, Vincent Rajkumar S, Reece D, Reiman T, Richardson PG, Roodman D, Rosiñol L, Miguel JS, Sezer O, Shah JJ, Shaughnessy J, Shimizu K, Shustik C, Siegel D, Singhal S, Sonneveld P, Spencer A, Stadtmauer E, Stewart K, Terpos E, Tosi P, Tricot G, Turesson I, Van Camp B, Van Ness B, Van Riet I, Broek IV, Vanderkerken K, Vescio R, Vesole D, Waage A, Wang M, Weber D, Westin J, Wheatley K, Zonder J. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study. Leukemia. 2012;26(1):149-157. doi: 10.1038/leu.2011.196. IF 9,561
  11. Morgan G, Johnsen HE, Goldschmidt H, Palumbo A, Cavo M, Sonneveld P, Miguel JS, Chim C, Browne P, Einsele H, Waage A, Turesson I, Spencer A, Hajek R, Ludwig H, Hemminki K, Houlston R. MAGIC (MyelomA Genetics International Consortium). Leuk Lymphoma. 2012;53(5):796-800 IF 2,580
  12. Kropff M, Giongco-Baylon H, Hillengass J, Robak T, Hajek R, Liebisch P, Goranov S, Hulin C, Blade J, Caravita T, Avet-Loiseau H, Moehler TM, Pattou C, Lucy L, Kueenburg E, Glasmacher A, Zerbib R, Facon T. Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial. Haematologica. 2012;97(5):784-91 IF 6,424
  13. Kubiczkova L, Sedlarikova L, Hajek R, Sevcikova S. TGF-β - an excellent servant but a bad master.J Transl Med. 2012 Sep 3;10:183. doi: 10.1186/1479-5876-10-183. IF 3,474
  14. Minarik J, Scudla V, Tichy T, Pika T, Bacovsky J, Lochman P, Zadrazil J. Induction treatment of light chain deposition disease with bortezomib - rapid hematological response with persistence of renal involvement. Leuk Lymphoma. 2012;(2):330-1 IF 2,580
  15. Minarik J, Pika T, Bacovsky J, Petrova P, Langova K, Scudla V. Prognostic value of hepatocyte growth factor, syndecan-1, and osteopontin in multiple myeloma and monoclonal gammopathy of undetermined significance. ScientificWorldJournal. 2012;2012:356128
  16. Minarik J, Pika T, Bacovsky J, Langova K, Scudla V. Low-dose acyclovir prophylaxis for bortezomib-induced herpes zoster in multiple myeloma patients. Br J Haematol. 2012;159(1):111-3. doi: 10.1111/j.1365-2141.2012.09233.x. IF 4,941
  17. Minařík J., Pika T., Bačovský J., Ščudla V.Kryoglobulinemická vaskulitida u nemocného s mnohočetným myelomem – kazuistika. Interní Med. 2012; 14(12): 478-480
  18. Minařík J., Ščudla V. Vliv prognostických ukazatelů na výsledky léčby lenalidomidem u nemocných s mnohočetným myelomem. Farmakoterapie;2012 (8) 5: 552-555
  19. Muthu Raja KR, Rihova L, Zahradova L, Klincova M, Penka M, Hajek R. Increased T regulatory cells are associated with adverse clinical features and predict progression in multiple myeloma. PLoS One. 2012;7(10):e47077. doi: 10.1371/journal.pone. 0047077. IF 4,092
  20. Muthu Raja KR, Kovarova L, Hajek R. Induction by Lenalidomide and Dexamethasone Combination Increases Regulatory Cells of Previously Untreated Multiple Myeloma Patients. Leuk Lymphoma. 2012;(7):1406-8  IF 2,580
  21. Muthu Raja KR, Kubiczkova L, Rihova L, Piskacek M, Vsianska P, Hezova R, Pour L, Hajek R. Functionally Suppressive CD8 T Regulatory Cells Are Increased in Patients with Multiple Myeloma: A Cause for Immune Impairment. PLoS One. 2012;7(11):e49446. IF 4,092
  22. Nemec P, Zemanova Z, Kuglik P, Michalova K, Tajtlova J, Kaisarova P, Oltova A, Filkova H, Holzerova M, Balcarkova J, Jarosova M, Rabasova J, Hruba M, Spicka I, Gregora E, Adam Z, Scudla V, Maisnar V, Schutzova M, Hajek R. Complex karyotype and translocation t(4;14) define patients with high-risk newly diagnosed multiple myeloma: results of CMG2002 trial. Leuk Lymphoma. 2012;53(5):920-7 IF 2,580
  23. Palumbo A, Hajek R, Delforge M, Kropff M, Petrucci MT, Catalano J, Gisslinger  H, Wiktor-Jędrzejczak W, Zodelava M, Weisel K, Cascavilla N, Iosava G, Cavo M, Kloczko J, Bladé J, Beksac M, Spicka I, Plesner T, Radke J, Langer C, Ben Yehuda D, Corso A, Herbein L, Yu Z, Mei J, Jacques C, Dimopoulos MA; MM-015 Investigators. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med. 2012;366(19):1759-69. IF 53,298
  24. Pika, T., Lochman, P., Klincová, M., Maisnar, V., Tichý, M., Zapletalová, J., Sandecká, V., Ščudla, V., Hájek, R.: Suprese alternativního páru imunoglobulinu koreluje s mírou rizikovosti MGUS výrazněji nežli suprese hladin polyklonálních imunoglobulinů – dílčí výsledky vyšetření HevyLiteTM u MGUS. Klin Biochem Metab 20(41),2012,2:63-71.
  25. Pika, T., Lochman, P., Minařík, J., Bačovský, J., Ščudla, V.: Úskalí interpretace výsledků společné analýzy hladin volných lehkých řetězců a elektroforézy séra. Klin Biochem Metab 20(41),2012,2:59-62.
  26. Sčudla V, Minařík J, Pika T. Light chain deposition disease. Vnitr Lek. 2012;58(1):38-43.
  27. Ščudla,V., Tichý,T., Minařík, J., Pika,T., Krejčí, K., Zadražil, J.: Onemocnění z depozice lehkých řetězců imunoglobulinu (light chain deposition disease). Klin Biochem Metab 2012; 20(4): 52-58.
  28. Ščudla,V.,Adam, Z.: Současné možnosti diagnostiky a léčby myelomové kostní nemoci v klinické praxi. Vnitř Lék 2012;58:164-174.
  29. Sedlarikova L, Kubiczkova L, Sevcikova S, Hajek R.Mechanism of immunomodulatory drugs in multiple myeloma. Leuk Res. 2012;36(10):1218-24. doi: 10.1016/j.leukres.2012.05.010. IF 2,923
  30. Vanicek J, Szturz P, Rehak Z, Kianicka B, Bulik M. Benefits of individual imaging methods for diagnosis and monitoring of activity of multiple myeloma. Klin Onkol. 2012;25(3):166-72.
  31. Zahradova L, Mollova K, Ocadlikova D, Kovarova L, Adam Z, Krejci M, Pour L, Krivanova A, Sandecka V, Hajek R. Efficacy and safety of Id-protein-loaded dendritic cell vaccine in patients with multiple myeloma - Phase II study results. Neoplasma. 2012;59(4):440-9. IF 1,440

Other projects

  1. Adam Z, Szturz P, Bučková P, Cervinková I, Koukalová R, Rehák Z, Krejčí M, Pour L, Zahradová L, Hájek R, Král Z, Mayer J. Interleukin-1 receptor blockade with anakinra provided cessation of fatigue, reduction in inflammation markers and regression of retroperitoneal fibrosis in a patient with Erdheim-Chester disease - case study and a review of literature. Vnitr Lek. 2012;58(4):313-8.
  2. Adam Z, Pour L, Matýšková M, Krejčí M, Tomíška M, Szturz P, Rehák Z, Koukalová R, Křikavová L, Nebeský T, Neuman C, Navrátil M, Hájek R, Král Z, Mayer J. Chronic disseminated intravascular coagulation (DIC) markers in a patient with multiple angiomatosis during treatment with anti-angiogenics: interferon α, thalidomide and lenalidomide. Vnitr Lek. 2012;58(2):145-53.
  3. Adam Z, Rehák Z, Koukalová R, Szturz P, Krejčí M, Pour L, Zahradová L, Moulis M, Kodet R, Nebeský T, Brejcha M, Adamová Z, Hájek R, Mayer J. Lenalidomide induced therapeutic response in a patient with aggressive multi-system Langerhans cell histiocytosis resistant to 2-chloro-deoxyadenosine and early relapsing after high-dose BEAM chemotherapy with autologous peripheral blood stem cell transplantation. Vnitr Lek. 2012;58(1):62-71.
  4. Adam Z, Matýšková M, Tomíška M, Rehák Z, Koukalová R, Křikavová L, Pour L, Krejčí M, Szturz P, Zahradová L, Mechl M, Moulis M, Vaníček J, Neuman C, Navrátil M, Veselý K, Hájek R, Mayer J. Six-year follow-up of a patient with multiple angiomatosis involving skeleton, thoracic and abdominal cavities and the gut wall. Klin Onkol. 2012;25(1):47-62.
  5. Adam Z, Veselý K, Motyčková I, Szturz P, Koukalová R, Rehák Z, Stouracová A, Vaníček J, Krejčí M, Pour L, Zahradová L, Hájek R, Král Z, Mayer J. Eyelids with yellow granulomas and cough - periocular xanthogranuloma associated with adult-onset asthma. A case study and an overview of clinical forms of juvenile xanthogranuloma and its therapy. Vnitr Lek. 2012;58(5):365-77.
  6. Adam Z, Szturz P, Duraš J, Pour L, Krejčí M, Rehák Z, Koukalová R, Navrátil M, Hájek R, Král Z, Mayer J. [Treatment of Langerhans cells histiocytosis by cladribin reached long-term complete remission in 9 out of 10 adult patients]. Klin Onkol. 2012;25(4):255-61.
  7. Adam Z, Chlupová G, Neumann A, Jakubcová B, Simonides J, Adamová Z, König J, Krupa P, Szturz P, Pour L, Krejčí M, Hájek R, Král Z, Mayer J.[Teleangiectasia hereditaria haemorrhagica--Osler-Weber-Rendu syndrome. Case study and treatment experience]. Vnitr Lek. 2012 Jun;58(6):477-89.
  8. Adam Z, Elleder M, Moulis M, Tichý M, Cervinková I, Rehák Z, Koukalová R, Fojtík Z, Hanke I, Pour L, Krejčí M, Zahradová L, Szturz P, Hájek R, Král Z, Mayer J. [The role of PET-CT in decision making on the treatment of localized nodular form of pulmonary AL-amyloidosis]. Vnitr Lek. 2012 Mar;58(3):241-52.
  9. Adam Z, Szturz P, Pour L, Krejčí M, Zahradová L, Tomíška M, Král Z, Koukalová R, Rehák Z, Mayer J. [Cladribine is highly effective in the treatment of Langerhans cell histiocytosis and rare histiocytic disorders of the juvenile xanthogranuloma group]. Vnitr Lek. 2012 Jun;58(6):455-65. Review.
  10. Adam Z,  Szturz P, Krejčí M, Pour L, Zahradová L, Řehák Z, Koukalová R,  Král Z, Vašků V, Mayer J: Kožní a mimokožní projevy histiocytózy z Langerhansových buněk v obrazech. Česká dermatovenerologie 2012; 2 (č. 1): 22-27
  11. Adam Z, Pour L, Krejčí M, Zahradová L, Szturz P, Koukalová R, Rehák Z, Nebeský T, Hájek R, Král Z, Mayer J. [The effect of lenalidomide on rare blood disorders: Langerhans cell histiocytosis, multicentric Castleman disease, POEMS syndrome, Erdheim-Chester disease and angiomatosis].Vnitr Lek. 2012 Nov;58(11):856-66.
  12. Adam Z, Štork M, Pour L, Krejčí M, Zahradová L, Sandecká V, Hájek R, Čermáková Z, Pospíšilová Y, Navrátil M, Král Z, Mayer M: Výsledky léčby AL-amyloidózy léčebnými režimy obsahujícími bortezomib, dexametazon a dále cyklofosfamid anebo doxorubicin. Vnitřní lék 2012; 58(12):896-903
  13. Minarik J, Scudla V, Bacovsky J, Pika T, Ctvrtlik F, Metelkova I, Myslivecek M. Comparison of imaging methods in POEMS syndrome. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2012 Mar;156(1):52-7.
  14. Szturz P, Rehák Z, Koukalová R, Adam Z, Krejčí M, Pour L, Zahradová L, Vaníček J, Nebeský T, Hájek R, Mayer J. Measuring diffuse metabolic activity on FDG-PET/CT: new method for evaluating Langerhans cell histiocytosis activity in pulmonary parenchyma. Nucl Med Biol. 2012;39(3):429-36 IF 3,023
  15. Szturz P, Adam Z, Rehák Z, Koukalová R, Slaisová R, Stehlíková O, Chovancová J, Klabusay M, Krejčí M, Pour L, Hájek R, Mayer J. Lenalidomide proved effective in multisystem Langerhans cell histiocytosis. Acta Oncol. 2012;51(3):412-5 IF 3,330
  16. Szturz P, Adam Z, Chovancová J, Stehlíková O, Klabusay M, Feit J, Křen L, Dorbová D, Fojtík Z, Obrovská M, Krejčí M, Pour L, Hájek R, Mayer J. Cytokine analysis in a patient with relapsing Kikuchi-Fujimoto disease. Leuk Lymphoma. 2012;53(4):743-5 IF 2,580
  17. Szturz P, Adam Z, Chovancová J, Stehlíková O, Klabusay M, Rehák Z, Koukalová R, Krejčí M, Pour L, Zahradová L, Hájek R, Mayer J. Lenalidomide: a new treatment option for Castleman disease. Leuk Lymphoma. 2012;53(10):2089-91 IF 2,580
  18. Szturz P, Adam Z, Moulis M, Smardová L, Klincová M, Slaisová R, Koukalová R, Rehák Z, Volfová P, Chovancová J, Stehlíková O, Mayer J. [Our experience in treatment of multicentric plasma-cell Castleman disease associated with vasculitis manifestations - case report and literature review]. Vnitr Lek. 2012 Sep;58(9):679-90.